Bone marrow macrophage STING signaling is a direct nexus linking marrow adipose expansion to NAD⁺ depletion and osteogenic decline in skeletal aging

The pursuit of understanding human longevity and healthy aging has long confronted the complex mechanics of skeletal deterioration. As humans age, the structural integrity of the skeletal system naturally degrades, leading to conditions such as osteoporosis, increased fracture risks, and chronic localized pain. Bone remodeling—a lifelong process wherein old bone tissue is broken down by specialized cells called osteoclasts and continuously replaced by new tissue formed by osteoblasts—becomes markedly imbalanced.

Historically, gerontologists and bone biologists understood that bone-forming osteoblasts originate from bone marrow mesenchymal stem cells (BMSCs), which possess a dual developmental fate: they can differentiate into either bone-forming osteoblasts or fat cells (adipocytes). With advancing age, a well-documented physiological shift occurs within the bone marrow niche. Instead of prioritizing osteogenesis, aging bone marrow progressively accumulates fat, driving an environment characterized by chronic, low-grade inflammation, often referred to by researchers as "inflammaging."

Despite decades of intensive study into this cellular shift, the precise molecular triggers linking expanding bone marrow fat to declining bone formation remained elusive. However, a landmark study recently published in the scientific journal Advanced Science by a team of researchers in China sheds critical new light on this biological puzzle. The research reveals that a specific immune signaling axis—the cGAS-STING pathway operating within bone marrow macrophages—acts as a direct biochemical bridge between marrow fat accumulation, cellular energy depletion, and skeletal degradation. By identifying this pathway, researchers have successfully demonstrated that interrupting this molecular signaling cascade can preserve bone density and structure in aging subjects.

Unraveling the cGAS-STING Pathway in Skeletal Aging

To comprehend the significance of this discovery, it is essential to examine the role of the cGAS-STING pathway within human and mammalian cell biology. The cyclic GMP-AMP synthase (cGAS) and stimulator of interferon genes (STING) pathway functions primarily as an innate immune defense mechanism. Under normal physiological conditions, cGAS detects double-stranded DNA that appears abnormally in the cell’s cytoplasm—compartments outside the nucleus where DNA does not belong. This misplaced genetic material typically signals a viral infection or bacterial invasion.

Upon detecting cytoplasmic DNA, cGAS produces a secondary messenger molecule called cGAMP. This messenger binds to and activates STING, which subsequently triggers downstream inflammatory signaling pathways designed to mount an immune response. However, as organisms age, this ancient defense mechanism increasingly misfires. Aging cells frequently accumulate damaged organelles, most notably mitochondria. When mitochondrial DNA leaks into the cytoplasm due to cellular stress or structural breakdown, it mimics a pathogen invasion, persistently triggering cGAS and chronically activating STING in the absence of any actual infection.

To investigate whether this pathway plays a central role in skeletal aging, the research team initiated a chronological and comparative analysis using murine models. By evaluating bone marrow samples from mice aged 3, 10, 18, and 24 months—representing the spectrum from young adulthood to advanced biological age—the scientists mapped a clear, progressive trajectory. They observed a marked age-related accumulation of DNA in the cytoplasm, elevated levels of cGAMP, and heightened phosphorylation (a reliable biochemical indicator of activation) of STING and its downstream signaling proteins.

When the investigators cross-examined various cell populations within the bone marrow microenvironment, macrophages emerged as the primary culprits. Macrophages exhibited the highest baseline expression of the Sting gene, and their STING activation levels scaled dramatically with age. This established immune-system-derived macrophages not merely as bystanders, but as plausible and potent therapeutic targets in the battle against age-related bone loss.

Experimental Interventions and Cellular Interactions

Armed with these foundational observations, the research team designed a series of targeted interventions to test whether macrophage STING activity is inherently harmful or merely a passive response to surrounding tissue damage.

Utilizing a macrophage-specific viral vector, the scientists genetically silenced the Sting gene in mice transitioning from 12 to 18 months of age—a critical developmental window during which skeletal degeneration accelerates rapidly in rodents. The results of this genetic intervention were striking. Mice subjected to macrophage-specific Sting silencing exhibited significant preservation of bone density and overall skeletal structure. Furthermore, histological analysis revealed an increase in markers associated with new bone deposition and a notable reduction in the total number of marrow fat cells.

Seeking to understand how activated macrophages exert such a detrimental influence on neighboring skeletal cells, the researchers conducted co-culture experiments. They discovered that macrophages derived from old mice severely impaired the developmental capacity of young BMSCs, inhibiting their ability to differentiate into functional, bone-forming osteoblasts. Crucially, old macrophages lacking functional STING lost this inhibitory potency, confirming that STING signaling is a direct driver of cellular dysfunction within the niche.

Investigating Upstream Triggers and the Role of DPP4

Having established the destructive role of macrophage STING, the investigators turned their attention upstream to identify what precisely triggers this pathway within the aging bone marrow microenvironment. They initially explored bacterial lipopolysaccharides (LPS), a component of bacterial cell walls known to activate innate immune receptors. Analyses confirmed that old mice harbored higher levels of endotoxins in both their blood and bone marrow, providing a baseline inflammatory stimulus.

However, the team suspected that internal metabolic shifts within the marrow were equally, if not more, influential. Given the age-related expansion of marrow adipose tissue, the researchers focused intensely on marrow fat cells and their secreted factors. They found that secretions from aging marrow fat cells strongly activated macrophage STING, both when applied in cell culture and when directly injected into the bone marrow of young mice.

Screening the bone marrow proteome, the researchers identified 44 distinct secreted proteins that were significantly elevated with age. Among these, dipeptidyl peptidase-4 (DPP4) stood out. Bone marrow fat cells released substantially higher quantities of soluble DPP4 than any other marrow cell type, with old fat cells shedding significantly more than their young counterparts.

To test the physiological impact of DPP4, the researchers injected the protein directly into the bone marrow of young mice for a period of four weeks. The treatment successfully replicated key features of skeletal aging: it worsened bone density and architecture while simultaneously activating macrophage STING. Conversely, genetically reducing Dpp4 expression specifically within marrow fat cells measurably improved structural health parameters, such as the spacing between trabeculae (the spongy bone networks).

Biochemical synergy soon became apparent. DPP4 alone did not independently trigger maximum STING activation; rather, it acted in concert with the broader inflammatory milieu of old bone marrow fluid. Mechanistic assays revealed that DPP4 binds directly to TLR4 (Toll-like receptor 4), a well-known cell-surface receptor involved in innate immunity. Blocking TLR4 successfully blunted STING activation, demonstrating that external DPP4-TLR4 signaling cooperates with internal mitochondrial damage—such as the leakage of mitochondrial DNA into the cytoplasm—to sustain chronic STING activity in aging macrophages.

The NAD⁺ Connection and Mitochondrial Respiration

The downstream consequences of chronic STING activation extend deeply into cellular metabolism, specifically targeting nicotinamide adenine dinucleotide (NAD⁺), a vital coenzyme found in all living cells that is essential for energy metabolism, DNA repair, and mitochondrial function.

The research team observed that intracellular NAD⁺ levels within bone marrow macrophages declined precipitously with age, driven by an age-related increase in NAD⁺-degrading enzymatic activity. Experimentally activating the STING pathway lowered macrophage NAD⁺ levels further, while suppressing cGAS or STING completely counteracted this effect. Further biochemical profiling revealed that STING signaling directly upregulates the expression of CD38, an enzyme renowned for its capacity to consume and degrade NAD⁺.

This enzymatic activity created a metabolic bottleneck for neighboring cells. CD38 positioned on the surface of macrophages degraded extracellular NAD⁺ and its key biosynthetic precursor, nicotinamide mononucleotide (NMN), effectively starving nearby BMSCs of the metabolic fuel required for optimal function.

Consequently, old BMSCs exhibited severely impaired mitochondrial respiration and diminished production of adenosine triphosphate (ATP), the primary cellular energy currency. Supplementing the culture media with NMN partially rescued these mitochondrial metrics, though the rescue was less effective in the presence of old or artificially activated macrophages. Notably, silencing cGAS or STING in macrophages restored normal mitochondrial respiration in co-cultured stem cells, proving that the metabolic crisis in bone-forming cells is largely secondary to macrophage-driven inflammation.

Pharmacological Validation and Therapeutic Implications

To translate these mechanistic insights into a potential clinical strategy, the research team tested a combined pharmacological intervention. They administered H-151, a selective small-molecule STING inhibitor, alongside NMN supplementation to mice aged 12 to 18 months.

The dual intervention yielded comprehensive physiological benefits. Treated mice maintained superior bone density and structural integrity compared to untreated age-matched controls. The therapy successfully increased new bone deposition, suppressed systemic and local inflammatory markers, and fully restored NAD⁺ levels and mitochondrial function within BMSCs.

To benchmark the efficacy of the H-151 and NMN combination, the researchers utilized alendronate—an established bisphosphonate drug commonly prescribed for human osteoporosis—as a positive control group. Remarkably, the improvements in bone structural integrity observed in the H-151/NMN combination group were largely comparable to those achieved with standard alendronate therapy, pointing toward a novel non-bisphosphonate paradigm for managing skeletal decline.

Despite these promising findings, study authors and independent specialists have noted several limitations. The study relied on a relatively small animal sample size, and the concurrent administration of two distinct therapeutic compounds (H-151 and NMN) makes it challenging to definitively isolate the precise individual contributions of STING inhibition versus NAD⁺ precursor supplementation. Furthermore, transitioning these murine findings to human clinical applications will require extensive translational research, pharmacokinetic optimization, and rigorous human clinical trials.

Broader Impact on the Longevity Science Landscape

The identification of the cGAS-STING-CD38 axis as a fundamental driver of skeletal aging represents a significant conceptual advance in biogerontology. For decades, therapeutic approaches to osteoporosis and bone degeneration have focused primarily on two fronts: slowing down bone resorption using anti-resorptive agents like bisphosphonates, or stimulating bone formation via anabolic hormone therapies.

By targeting the immunological and metabolic cross-talk between marrow fat accumulation, macrophage activation, and systemic NAD⁺ depletion, this study introduces a completely new upstream intervention point. It bridges the fields of immunometabolism, stem cell biology, and aging research, suggesting that age-related tissue degradation is not merely a consequence of wear and tear, but an actively driven pathological signaling process.

As researchers continue to dissect the complex interplay between cellular senescence, fat accumulation, and immune signaling, the prospect of pharmacological interventions that simultaneously calm chronic inflammation and restore metabolic cellular health grows increasingly tangible. While significant developmental hurdles remain before these preclinical insights reach clinical practice, the discovery offers a compelling roadmap for preserving skeletal vitality and extending healthspan well into advanced age.